trial

Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes

NCTId NCT05414058
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 35 (actual)
Sponsored by The Royal Ottawa Mental Health Centre
Primary completion 2024-08-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
35 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2022-09-09
Primary completion
2024-08-21
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Apo-Methylphenidate ER

Sponsors

The Royal Ottawa Mental Health CentreLead Sponsor

Investigators

1
Naista Zhand, M.D.Principal Investigator

Sites

1 total
Ottawa, Canada

Linked catalysts

1
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Function — primary completion2024-08-21

Facts & assertions

4 sourced
Enrollment
35
Phase
PHASE2
Primary Completion Date
2024-08-21
Status
COMPLETED
relationships
The graph out of here
drug
Apo-Methylphenidate ER
drug
lead_sponsor
The Royal Ottawa Mental Health Centre
company
indication
Schizophrenia
indication
Schizophrenia Schizoaffective
indication
Psychotic Disorders
indication
investigator
Naista Zhand, M.D.
person